- Home
- GLO vs ACHV Comparison
GLO vs ACHV Comparison
Compare GLO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | ACHV |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.3M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GLO | ACHV |
|---|---|---|
| Price | $5.92 | $4.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 170.5K | ★ 907.1K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $1.84 |
| 52 Week High | $5.18 | $6.03 |
Technical Indicators
Market Signals| Indicator | GLO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 36.55 |
| Support Level | $5.88 | $5.12 |
| Resistance Level | $5.99 | $5.70 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 35.19 | 7.30 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.